Clinical trial
A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate…
NCT00448383 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00448383 |
|---|---|
| Title | A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis |
| Official title | An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis |
| Acronym | ReAct |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | adalimumab |
| Enrollment | 6,610 |
| Start date | Sep 1, 2002 |
| Primary completion | Nov 1, 2004 |
| First posted | Mar 16, 2007 |
| Last update posted | Aug 4, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: